Under the Defence Product Act, the agency greenlit $32.4 million for Manus Bio, a biomanufacturing company in Waltham, Mass., and up to $12 million for Antheia, an active pharmaceutical ingredient manufacturer in Menlo Park, Calif.
With these funds, Manus and Antheia will focus on expanding capabilities to produce key starting materials and APIs for essential medicines, according to a Nov. 25 news release from ASPR.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
